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Results: Median follow and median age were 75 m (range: 
60-99) and 74 y (57-84) respectively, while median Gleason 
score( GS) was 6 (3-10):GS<7: 75; GS=7: 39; GS>7: 13 ; 
missing:2. 73 pts were staged as T1, 46 as T2: 6 as T3; and 
for 3 pts the stage was unclear (Tx). The median initial Psa ( 
iPsa) was 7.8 (1.2-826). The 75-m bRFS was 92.5% (LR: 94.2%; 
IR: 96.9%; HR: 84.5%); OS was 94.6% ( LR:95.9%; IR: 95.8%; 
HR: 91.1%) and CSS was 97.4% (LR: 100%;IR:94.5%;HR: 97.1%). 
AD and class risk were not correlated with bRFS/OS/CSS. The 
incidence of G3 toxicity was around 6% with drastically 
reduction of the prevalence at the last follow-up for both 
≥G2 and ≥G3 toxicities indicating that symptoms were 
recovered in most patients. 
 
Conclusion: The combination of pelvic LN irradiation and 
high dose to the prostate, (EQD2=88Gy) delivered with daily 
image-guided, intensity-modulated, moderate 
hypofractionation resulted in an excellent 75-m outcome, 
even in IR/HR patients. This encouraging result seems to be 
without correlation with AD considering the long time 
elapsed between the end of the AD and the last follow up of 
pts. The toxicity profile was acceptable  
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Purpose or Objective: To compare clinical results of 
adjuvant and salvage radiotherapy after radical 
prostatectomy for prostate cancer and to determinate 
prognostic factors of biochemical relapse free survival 
(BRFS).  
 
Material and Methods: 302 patients were treated at our 
institution over a 12-year period. Overall survival and 
biochemical-relapse free survival were analized using Kaplan-
Meier and multivariate Cox regression analysis was used to 
assess differences between groups. 
 
Results: Mean age at diagnosis was 65 years (42-80). All 
patients underwent radical prostatectomy combined with 
pelvic lymphadenectomy in 47.1% of cases. Neoadjuvant 
androgen deprivation before surgery was given to 36.5% . 
Mean pre-RT PSA of 0.46ng/ml (0-12.8 ng/ml). Adjuvant RT 
(ART) was performed in 113 patients and salvage RT (SRT) in 
183 (9 for local recurrence) and mean dosis to surgical bed 
was 70 Gy (60-76 Gy). The distribution of patients by pT 
stage was pT2a/b (30.3%), pT2c (35%), pT3 (29%) and pT4 
(2.3%). Upgrade in Gleason Score between transrectal biopsy 
and prostatectomy was experienced by 46.7% of patients. 
Positive surgical margins were reported in 56.5% of cases. 
Mean follow-up was 58.85 months (1-153 months). Overall 
survival at 5 and 10 years was 98.1% and 94.3%, respectively 
and BRFS at 5 and 10 years was 76.5% vs. 61.8%, respectively. 
The timing of RT (ART vs. SRT) and pre-RT PSA <0.5 ng/ml 
were significant predictors of longer BRFS.  
 
 
 
Conclusion: Postoperative radiation therapy provides 
excellent long-term overall survival results with an aceptable 
BRFS with pre-RT PSA <0.5 ng/ml and adjuvant radiotherapy 
as predictors of better outcomes. 
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Purpose or Objective: To facilitate shared decision making, 
we aim to develop a decision aid tool that helps prostate 
cancer patients to understand the benefits and side-effects 
of the treatments offered by their clinicians.  
The tool should follow the International Patient Decision Aid 
Standard, and therefore patient’s and doctor’s views on 
decisional needs must be considered. The tool should have a 
new slant on existing tools: it should personalize the 
information, guide patients to identify their preferences, and 
help doctors to understand patients’ preferences. 
 
Material and Methods: Patients and clinicians were 
interviewed to assess their decisional needs. A prototypical 
tool was developed. Its clarity and acceptability was 
evaluated by the technology acceptance questionnaire (5-
Likert scale). 
 
Results: Prostate cancer patients already treated (N=16) 
mentioned the need of visual and free of medical jargon 
information about prostate cancer, treatments, side-effects, 
and treatment experience. Medical specialists (N=8; radiation 
oncologists, urologists, nurses) mentioned the need of 
information about basic anatomy, contraindications, hospital 
specific figures, and psychological support. Results about 
comprehensibility of the prototypical tool showed that most 
the patients fully agree (69%) or agree (31%) that the 
prototypical tool provides clear information about 
treatments, their side-effects, the differences between 
treatments, and eases comparison. Likewise, most of the 
patients fully agree (69%) or agree (31%) on using the tool if 
it would became available, and will recommend it to others 
(67% fully agree; 33% agree).  
After considering the views of patients and medical 
specialists, the result is an alpha version of a web-decision 
aid tool for prostate cancer patients 
(http://www.treatmentchoice.info). The tool personalizes 
information for each patient. It assists patients to decide 
what their preferences regarding quality of life and 
treatment experience are, and to think how important are 
the side-effects for them. It provides a printed report of 
patients’ preferences to be using during consultation. Fig 
below gives an impression. 
 
